BLA 761392 · Samsung Bioepis CO LTD
Denosumab-Dssb
Denosumab-Dssb · Subcutaneous · RANK Ligand Inhibitor
Last checked: Nov 20, 2026Latest source record: Oct 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Oct 29, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
287
81 Phase 3, 26 recruiting
FAERS reports
16,588
15,953 serious, 1,936 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Ospomyv in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Ospomyv in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and...
What it is approved for
From the label in effect Nov 11, 2025.
Ospomyv is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Ospomyv is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Ospomyv is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Ospomyv is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain...
Mechanism: Denosumab products bind to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Denosumab products prevent RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 29, 2025 Original approval · Efficacy LetterLabelMedication Guide
- Feb 13, 2025 Original approval LabelLetterMedication Guide
4 products under this application
- DENOSUMAB-DSSB · DENOSUMAB-DSSB 60MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription
- OSPOMYV · DENOSUMAB-DSSB 60MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription
- DENOSUMAB-DSSB · DENOSUMAB-DSSB 70MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription
- XBRYK · DENOSUMAB-DSSB 70MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Denosumab" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Denosumab in the Treatment of Postmenopausal OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00089791 · 7,808 participants · Start Aug 1, 2004 · Primary completion Jun 17, 2008
Drug: placebo; Denosumab · For: Osteoporosis
- Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01575834 · 7,180 participants · Start Mar 15, 2012 · Primary completion Dec 14, 2015
Drug: Romosozumab; Placebo and 1 more · For: Postmenopausal Osteoporosis
Sites: Tucson, Arizona; Laguna Hills, California; Los Angeles, California · 218 sites in all
- Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00523341 · 4,550 participants · Start Aug 7, 2007 · Primary completion Jul 19, 2015
Drug: Denosumab · For: Osteopenia; Osteoporosis
- Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)Pivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT01077154 · 4,509 participants · Start Jun 2, 2010 · Primary completion Aug 31, 2017
Drug: Placebo; Denosumab · For: Breast Cancer
Sites: Birmingham, Alabama; Tucson, Arizona; Jonesboro, Arkansas · 459 sites in all
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00556374 · 3,420 participants · Start Dec 18, 2006 · Primary completion Oct 7, 2014
Drug: Placebo; Denosumab and 2 more · For: Breast Cancer
Sites: Baden, Austria; Braunau am Inn, Austria; Dornbirn, Austria · 46 sites in all
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic RefracturePivotal-lookingRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT05866029 · 2,478 participants (planned) · Start May 26, 2023 · Primary completion Sep 30, 2026
Drug: Denosumab; Teriparatide · For: Osteoporotic Fractures
Sites: Beijing, China; Changchun, China; Changsha, China · 58 sites in all
- A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00321464 · 2,049 participants · Start Apr 1, 2006 · Primary completion Jul 20, 2009
Drug: Denosumab; Zoledronic Acid · For: Bone Metastases
- Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate CancerPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00321620 · 1,904 participants · Start Apr 1, 2006 · Primary completion Oct 1, 2009
Drug: zoledronic acid; denosumab · For: Bone Metastases
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- osteonecrosis of jaw1,555
- diarrhoea1,176
- fatigue1,137
- nausea1,086
- malignant neoplasm progression1,072
- neutropenia981
- metastases to bone857
- off label use845
- anaemia758
- vomiting619
- dyspnoea608
- hypocalcaemia608
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 67 |
| 2011 | 136 |
| 2012 | 214 |
| 2013 | 358 |
| 2014 | 474 |
| 2015 | 662 |
| 2016 | 748 |
| 2017 | 636 |
| 2018 | 956 |
| 2019 | 1,013 |
| 2020 | 1,063 |
| 2021 | 1,495 |
| 2022 | 1,772 |
| 2023 | 1,781 |
| 2024 | 1,728 |
| 2025 | 1,748 |
| 2026 | 1,734 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Händel MN, Cardoso I, von Bülow C, et al. · BMJ 2023 · Systematic Review, Network Meta-Analysis
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Cosman F, Crittenden DB, Adachi JD, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG, Wagman RB, Brandi ML, et al. · Lancet Diabetes Endocrinol 2017 · Clinical Trial, Phase III, Multicenter Study
- Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR, San Martin J, McClung MR, et al. · N Engl J Med 2009 · Multicenter Study, Randomized Controlled Trial
- Treatment of hypercalcaemia of malignancy in adults.
Mc Donald D, Drake MT, Crowley RK · Clin Med (Lond) 2023 · Meta-Analysis, Systematic Review
Sponsor: Samsung Bioepis CO LTD · Also marketed as Ospomyv, Xbryk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.